Loading...
OTCM
RDGL
Market cap40mUSD
Jul 10, Last price  
0.08USD
1D
0.85%
1Q
4.80%
IPO
-78.07%
Name

Vivos Inc

Chart & Performance

D1W1MN
OTCM:RDGL chart
P/E
P/S
591.55
EPS
Div Yield, %
Shrs. gr., 5y
15.23%
Rev. gr., 5y
57.75%
Revenues
68k
+144.25%
130,055268,242320,363360,613393,603247,968140,60324,10824,1088,1084,05409,5007,00014,88736,49919,50027,99568,379
Net income
-3m
L+5.36%
-2,869,000-6,159,000-3,992,000-4,055,000-2,750,000-8,586,000-3,471,000-18,109,0006,233,000-9,855,000-6,419,000-7,703,000-1,610,000-957,000-2,528,000-2,470,000-2,895,000-2,910,000-3,066,017
CFO
-2m
L+22.19%
-312,978-1,543,998-1,013,028-634,319-858,844-1,799,243-2,036,470-1,135,926-1,193,105-1,926,713-1,288,075-700,454-837,113-875,807-963,819-1,120,058-1,293,023-1,684,039-2,057,743

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Vivos Inc. is a medical technology company focused on radiation oncology, specializing in the development of internal radiation therapy devices for managing tumors that cannot be surgically removed. Their offerings include RadioGel, an injectable particle-gel that utilizes yttrium-90 for targeted radiation treatment of cancerous growths in both humans and animals. Additionally, the company provides IsoPet, a specific treatment for solid tumors found in animals. Established in 1994, Vivos Inc. is based in Richland, Washington. It previously operated under the name Advanced Medical Isotope Corporation before rebranding to Vivos Inc. in December 2017.
IPO date
Aug 08, 2001
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT